Numero 3, Volume 15 - luglio 2012 - Nuova Serie - AMD

Editoriale A. Ceriello, M. Gallo, S. Gentile, C.B. Giorda, A. De Micheli
tes Association 2008 clinical practice guidelines for the prevention
and management of diabetes in Canada. Canadian Journal
of Diabetes 32:S1–S201, 2008.
5. National Institute for Health and Clinical Excellence -
NICE (2008) Type 2 diabetes: the management of type 2
diabetes: NICE Clinical Guideline 87. http://www.nice.
org.uk/CG66.
6. Home P, Mant J, Diaz J, Turner C. Management of type 2 diabetes:
summary of updated NICE guidance. British Medical
Journal 336:1306–1308, 2008.
7. AMD-SID (Diabete Italia), Standard italiani per la cura del diabete
mellito http://www.aemmedi.it/pages/linee-guida_e_raccomandazioni/.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. New
England Journal of Medicine 356:2457–2471, 2007.
9. US Food and Drug Administration (2011) FDA Drug Safety
Communication: update to ongoing safety review of Lantus (insulin
glargine) and possible risk of cancer. http://www.fda.gov/
Drugs/DrugSafety/ucm239376.htm.
10. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis,
pancreatic, and thyroid cancer with glucagonlike peptide-1-based
therapies. Gastroenterology 141:150–156, 2011.
11. US Food and Drug Administration (2011) FDA Drug Safety
Communication: update to ongoing safety review of Actos (pioglitazone)
and increased risk of bladder cancer. http://www.fda.
gov/Drugs/DrugSafety/ucm259150.htm.
12. European Medicines Agency (2011) European Medicines
Agency recommends new contraindications and warnings for
pioglitazone to reduce small increased risk of bladder cancer.
http://www.ema.europa.eu/docs/en_GB/document_library/
Press_release/2011/07/WC500109176.pdf.
13. Gallo M, Esposito K, Giugliano D. Diabetes medications and
cancer: A way out of uncertainty. Diabetes Research and Clinical
Practice May 2, 2012 (Epub ahead of print), http://dx.doi.
org/10.1016/j.diabres.2012.04.007.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive
glucose lowering in type 2 diabetes. New England Journal of
Medicine 358:2545–2559, 2008.
15. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose
control and vascular outcomes in patients with type 2 diabetes.
New England Journal of Medicine 358:2560–2572, 2008.
16. Duckworth W, Abraira C, Moritz T et al; VADT Investigators.
Glucose control and vascular complications in veterans with
type 2 diabetes. New England Journal of Medicine 360:129–
139, 2009.
17. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose
control and macrovascular outcomes in type 2 diabetes. Diabetologia
52:2288–2298, Erratum 52:2470, 2009.
18. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control
and the prevention of cardiovascular events: implications of
the ACCORD, ADVANCE, and VA diabetes trials: a position statement
of the American Diabetes Association and a scientific statement
of the American College of Cardiology Foundation and
the American Heart Association. Diabetes Care 32:187–192,
2009.
19. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered approach.
Position statement of the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD).
Diabetologia 55: 1577-1596, 2012.
20. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of
AMD
Il Giornale di AMD 2012;15:141-147
Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach:
Position Statement of the American Diabetes Association
(ADA) and the European Association for the Study of Diabetes
(EASD). Diabetes Care 35: 1364-1379, 2012.
21. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth
S. Individualizing glycemic targets in type 2 diabetes mellitus:
implications of recent clinical trials. Annals of Internal Medicine
154:554–559, 2011.
22. Schernthaner G, Barnett AH, Betteridge DJ et al. Is the ADA/
EASD algorithm for the management of type 2 diabetes (January
2009) based on evidence or opinion? A critical analysis. Diabetologia
53:1258-1569, 2010.
23. Ceriello A. Consensus algorithm of the American Diabetes Association
and the European Association for the Study of Diabetes:
some concerns. Diabetologia 52:1696-1697, 2009.
24. Cavalot F, Pagliarino A, Valle M et al. Postprandial blood glucose
predicts cardiovascular events and all-cause mortality in Type
2 diabetes in a 14-year follow-up: Lessons from the San Luigi
Gonzaga Diabetes Study. Diabetes Care 34:2237-2243, 2011.
25. International Diabetes Federation Clinical Guidelines Task Force
(2011) Guideline for management of postmeal glucose in diabetes.http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes.
26. International Diabetes Federation Clinical Guidelines Task Force
(2009) Guideline on self-monitoring of blood glucose in noninsulin
treated type 2 diabetes. http://www.idf.org/guidelines/
self-monitoring.
27. Durán A, Martín P, Runkle I et al. Benefits of self monitoring
blood glucose in the management of new onset Type 2 diabetes
mellitus: the St Carlos Study, a prospective randomized clinicbased
interventional study with parallel groups. Journal of Diabetes
2: 203-211, 2010.
28. Polonsky WH, Fisher L, Schikman CH et al. Structured, self-monitoring
blood glucose significantly reduces A1C levels in poorly
controlled, noninsulin-treated type 2 diabetes: results from the
Structured Testing Program study. Diabetes Care 34:262-267,
2011.
29. Franciosi M, Lucisano G, Pellegrini F et al. ROSES: role of selfmonitoring
of blood glucose and intensive education in patients
with Type 2 diabetes not receiving insulin. A pilot randomized
clinical trial. Diabetic Medicine 28:789-796, 2011.
30. Scavini M, Bosi E, Ceriello A et al. Prospective, randomized
trial on intensive SMBG management added value in non-insulin-treated
T2DM patients (PRISMA): a study to determine
the effect of a structured SMBG intervention. Acta Diabetol
dec 2011 http://link.springer.com/article/10.1007/s00592-
011-0357-y.
31. Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli;
On Behalf Of The Associazione Medici Diabetologi. Personalizing
treatment in type 2 diabetes: a self-monitoring of blood
glucose inclusive innovative approach. Diabetes Technology
and Therapeutics 14:373-378, 2012.
32. Working Group on Personalized Therapy in Type 2 Diabetes Set
Up by the Italian Association of Medical Diabetologists - AMD
(2011) Personalization of therapy in type 2 diabetes. http://
www.aemmedi.it/algoritmi/.
33. Ceriello A, Gallo M, Gentile S, Giorda CB, De Micheli A; on behalf
of Associazione Medici Diabetologi (AMD). To what extent
is the new position statement of the American 5 Diabetes Association
(ADA) and the European Association 6 for the Study of
Diabetes (EASD) ‘personalised’? Diabetologia July 2012 (Epub
ahed of print), DOI 10.1007/s00125-012-2642-x.
147